Streetbeat News

Stock Prices

IART

Integra Lifesciences (NASDAQ:IART) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, 3 indifferent, and 1 somewhat bearish. The average price target is $48.67, representing an upside from the current price of $42.5. However, this average represents a 13.09% decrease from the previous average price target of $56.00.

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 1:00 pm

RCUS

Arcus Biosciences (NYSE:RCUS) has received positive ratings from 5 analysts in the last quarter, with an average price target of $49.8, indicating a potential upside from the current price of $23.03. The average price target has increased by 22.96% from the previous average of $40.50.

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 1:00 pm

ADI

Analysts have provided various ratings for Analog Devices (NASDAQ:ADI) within the last quarter, with a total of 2 bullish, 4 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for ADI is $208.5, a decrease of 1.42% from the previous average price target of $211.50.

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 1:00 pm

CIVI

Over the past three months, four analysts have published their opinions on Civitas Resources (NYSE:CIVI) stock. The company has received two bullish, one somewhat bullish, and one indifferent rating. The average 12-month price target for the company is $86.75, which is a 5.79% increase from the previous average price target of $82.00.

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 1:00 pm

BDSX

EFSH

KINS

NANX

Insiders at four companies have recently made notable purchases of their own stocks. The CEO of 1847 Holdings (NYSE:EFSH) bought 75,000 shares, a 10% owner of Nanophase Technologies (OTC:NANX) acquired 85,847 shares, the COO of Kingstone Companies (NASDAQ:KINS) purchased 3,072 shares, and a director at Biodesix (NASDAQ:BDSX) bought 128,363 shares. These transactions may indicate the insiders' confidence in their companies' prospects.

Portfolio Pulse from Lisa Levin

August 24, 2023 | 12:53 pm

TLT

The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT) traded higher during Wednesday's trading session. Kevin Kelly of Kelly Intelligence noted that the ETF had about 1.72 times the amount of calls traded versus puts. Traders anticipate the ETF to continue its upward trend through October. However, it was down 0.5% in Thursday's pre-market trading session.

Portfolio Pulse from Lisa Levin

August 24, 2023 | 12:48 pm

NVDA

SNOW

Snowflake Inc (NYSE:SNOW) reported better-than-expected Q2 results with a 36% YoY increase in revenue to $674.02 million, beating the consensus estimate of $662.24 million. The company also reported quarterly earnings of 25 cents per share, surpassing analyst estimates of 10 cents per share. Snowflake's stock didn't rise until NVIDIA Corp (NASDAQ:NVDA) reported strong Q2 results due to increased AI demand. Several analysts updated their ratings and price targets for Snowflake following the results.

Portfolio Pulse from Adam Eckert

August 24, 2023 | 12:48 pm

SPY

The month-on-month (MoM) Durable Goods Orders Excluding Defense for July has shown a decrease of 5.4%, compared to a prior increase of 5.9%.

Portfolio Pulse from Benzinga Newsdesk

August 24, 2023 | 12:47 pm

SNOW

Snowflake's shares are trading higher following the company's release of better-than-expected Q2 financial results and guidance.

Portfolio Pulse from Benzinga Newsdesk

August 24, 2023 | 12:45 pm

MDT

OTSKF

OTSKY

Medtronic's Symplicity Spyral RDN System, a device for treating high blood pressure, has faced a regulatory setback as the FDA Circulatory System Devices Panel voted against its approval, citing that the risks do not outweigh the benefits. Meanwhile, the same panel backed a similar device by Recor Medical and its parent company, Otsuka Medical Devices. Medtronic's shares fell 1.24% in premarket trading following the news.

Portfolio Pulse from Vandana Singh

August 24, 2023 | 12:45 pm